Natco Pharma to acquire Dash Pharma

Published On 2021-12-16 12:05 GMT   |   Update On 2021-12-16 12:05 GMT
Advertisement

Hyderabad: Drug maker, Natco pharma, has recently announced that the company through its affiliates is proposing to enter into an agreement to acquire 100 percent stake in Dash Pharmaceuticals LLC.

The acquisition is subjected to satisfactory completion of due diligence, execution of definitive agreements and compliance with statutory requirements. This acquisition provides NATCO with a front-end to engage with its customers directly in the USA which is the largest pharmaceutical market in the world.

Advertisement

"The indicative time period for completion of the acquisition is January 31, 2022," the company informed in a BSE filing.

The company further informed that the nature of consideration for the deal is US$ 18 million in cash.

Dash is a front-end pharmaceutical sales, marketing and distribution entity based in New Jersey, USA which is expected to have approximate net sales of USD 15 million for the year ending December 2021.

Read also: Natco Pharma launches cancer drug Tipanat in India

Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million.

The company has seven manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc

Read also: Natco Pharma Marketing Partner Launches Generic Version Of Afinitor In US

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News